Alpha 1a adrenergic receptor antagonists
US6376503B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 17, 1998 |
| Grant date | Apr 23, 2002 |
| Priority date | — |
| Expiry date | Jun 17, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/10
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.